Aurobindo Pharma Limited (AUROPHARMA.BO)
INR 1264.95
(1.37%)
INR 1264.95
(1.37%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 152.2 Billion INR | 16.74% |
| 2022 | 130.38 Billion INR | 39.48% |
| 2021 | 93.47 Billion INR | -21.61% |
| 2020 | 119.25 Billion INR | -1.47% |
| 2019 | 121.02 Billion INR | -3.65% |
| 2018 | 125.61 Billion INR | 33.37% |
| 2017 | 94.18 Billion INR | 36.99% |
| 2016 | 68.75 Billion INR | -24.47% |
| 2015 | 91.02 Billion INR | 22.51% |
| 2014 | 74.29 Billion INR | 30.03% |
| 2013 | 57.14 Billion INR | 22.72% |
| 2012 | 46.56 Billion INR | 19.76% |
| 2011 | 38.87 Billion INR | 13.73% |
| 2010 | 34.18 Billion INR | 15.57% |
| 2009 | 29.57 Billion INR | -0.81% |
| 2008 | 29.81 Billion INR | 18.93% |
| 2007 | 25.07 Billion INR | -4.19% |
| 2006 | 26.16 Billion INR | 39.45% |
| 2005 | 18.76 Billion INR | 32.6% |
| 2004 | 14.15 Billion INR | 24.05% |
| 2003 | 11.4 Billion INR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q1 | - INR | -100.0% |
| 2023 Q2 | 157.29 Billion INR | 0.0% |
| 2023 Q4 | 152.2 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 FY | 152.2 Billion INR | 16.74% |
| 2022 FY | 130.38 Billion INR | 39.48% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q2 | 116.26 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q4 | 130.38 Billion INR | 0.0% |
| 2021 Q4 | 93.47 Billion INR | 0.0% |
| 2021 FY | 93.47 Billion INR | -21.61% |
| 2021 Q2 | 105.99 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q3 | - INR | -100.0% |
| 2020 Q4 | 119.25 Billion INR | 0.0% |
| 2020 FY | 119.25 Billion INR | -1.47% |
| 2020 Q2 | 121.46 Billion INR | 0.0% |
| 2019 Q2 | 120.95 Billion INR | 0.0% |
| 2019 FY | 121.02 Billion INR | -3.65% |
| 2019 Q4 | 121.02 Billion INR | 0.0% |
| 2018 FY | 125.61 Billion INR | 33.37% |
| 2018 Q2 | 111.94 Billion INR | 0.0% |
| 2018 Q4 | 125.61 Billion INR | 0.0% |
| 2017 Q4 | 94.18 Billion INR | 0.0% |
| 2017 FY | 94.18 Billion INR | 36.99% |
| 2017 Q2 | 92.98 Billion INR | 0.0% |
| 2016 FY | 68.75 Billion INR | -24.47% |
| 2016 Q2 | 73.28 Billion INR | 0.0% |
| 2016 Q4 | 68.75 Billion INR | 0.0% |
| 2015 Q2 | 87.61 Billion INR | 0.0% |
| 2015 Q4 | 91.02 Billion INR | 0.0% |
| 2015 FY | 91.02 Billion INR | 22.51% |
| 2014 Q2 | 68.66 Billion INR | 0.0% |
| 2014 Q4 | 74.29 Billion INR | 0.0% |
| 2014 FY | 74.29 Billion INR | 30.03% |
| 2013 Q2 | 53.37 Billion INR | 0.0% |
| 2013 Q4 | 57.14 Billion INR | 0.0% |
| 2013 FY | 57.14 Billion INR | 22.72% |
| 2012 Q4 | 46.56 Billion INR | 0.0% |
| 2012 FY | 46.56 Billion INR | 19.76% |
| 2011 Q4 | 38.87 Billion INR | 0.0% |
| 2011 FY | 38.87 Billion INR | 13.73% |
| 2010 FY | 34.18 Billion INR | 15.57% |
| 2009 FY | 29.57 Billion INR | -0.81% |
| 2008 FY | 29.81 Billion INR | 18.93% |
| 2007 FY | 25.07 Billion INR | -4.19% |
| 2006 FY | 26.16 Billion INR | 39.45% |
| 2005 FY | 18.76 Billion INR | 32.6% |
| 2004 FY | 14.15 Billion INR | 24.05% |
| 2003 FY | 11.4 Billion INR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Ajanta Pharma Limited | 10.71 Billion INR | -1321.128% |
| Amrutanjan Health Care Limited | 783.82 Million INR | -19318.53% |
| Sigachi Industries Limited | 2.53 Billion INR | -5913.084% |
| Bal Pharma Limited | 2.51 Billion INR | -5960.947% |
| Ind-Swift Laboratories Limited | 2.28 Billion INR | -6548.163% |
| Medico Remedies Limited | 438.24 Million INR | -34631.132% |
| Lasa Supergenerics Limited | 541.92 Million INR | -27986.377% |
| Venus Remedies Limited | 1.39 Billion INR | -10828.138% |
| Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | -3809.864% |
| Alpa Laboratories Limited | 307.12 Million INR | -49459.165% |
| Nectar Lifesciences Limited | 11.21 Billion INR | -1256.801% |
| Shilpa Medicare Limited | 12.93 Billion INR | -1076.937% |
| Aarti Drugs Limited | 11.5 Billion INR | -1223.08% |
| Lupin Limited | 96.23 Billion INR | -58.158% |
| Zydus Lifesciences Limited | 71.79 Billion INR | -112.011% |
| Windlas Biotech Limited | 1.76 Billion INR | -8534.884% |
| Suven Life Sciences Limited | 148.62 Million INR | -102312.916% |
| Eris Lifesciences Limited | 38.26 Billion INR | -297.739% |
| Valiant Laboratories Limited | 1.05 Billion INR | -14282.783% |
| J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | -1321.434% |
| Solara Active Pharma Sciences Limited | 14.14 Billion INR | -976.14% |
| Ipca Laboratories Limited | 33.74 Billion INR | -351.08% |
| Bliss GVS Pharma Limited | 2.1 Billion INR | -7117.537% |
| Achyut Healthcare Limited | 2.01 Million INR | -7561107.154% |
| Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 17.085% |
| Bajaj HealthCare Limited | 4.86 Billion INR | -3026.9% |
| RPG Life Sciences Limited | 1.38 Billion INR | -10927.902% |
| Mankind Pharma Limited | 23.87 Billion INR | -537.526% |
| Laurus Labs Limited | 42.71 Billion INR | -256.335% |
| Piramal Pharma Limited | 74 Billion INR | -105.673% |
| Syncom Formulations (India) Limited | 1.16 Billion INR | -12962.621% |
| Torrent Pharmaceuticals Limited | 82.05 Billion INR | -85.505% |
| Alembic Pharmaceuticals Limited | 16.27 Billion INR | -835.289% |
| Glenmark Pharmaceuticals Limited | 65.11 Billion INR | -133.766% |
| Unichem Laboratories Limited | 8.06 Billion INR | -1786.26% |
| Sequent Scientific Limited | 8.27 Billion INR | -1739.527% |
| Novartis India Limited | 1.8 Billion INR | -8350.786% |
| Wanbury Limited | 3.15 Billion INR | -4723.523% |
| Suven Pharmaceuticals Limited | 2.03 Billion INR | -7382.299% |
| Wockhardt Limited | 39.87 Billion INR | -281.758% |
| Themis Medicare Limited | 1.88 Billion INR | -7963.905% |
| Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -51189.628% |
| Jubilant Pharmova Limited | 61.27 Billion INR | -148.404% |
| Glenmark Life Sciences Limited | 5.18 Billion INR | -2837.851% |
| Dr. Reddy's Laboratories Limited | 106.96 Billion INR | -42.292% |
| Divi's Laboratories Limited | 18.99 Billion INR | -701.512% |
| NATCO Pharma Limited | 10.53 Billion INR | -1345.187% |
| Gufic Biosciences Limited | 5.59 Billion INR | -2618.076% |
| IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | -2304.953% |
| Ind-Swift Limited | 13.45 Billion INR | -1031.402% |
| Procter & Gamble Health Limited | 2.56 Billion INR | -5842.804% |
| FDC Limited | 3.7 Billion INR | -4003.493% |
| Krebs Biochemicals & Industries Limited | 2.97 Billion INR | -5018.073% |
| Granules India Limited | 22.95 Billion INR | -563.085% |
| Medicamen Biotech Limited | 940.36 Million INR | -16085.925% |
| Alkem Laboratories Limited | 48.6 Billion INR | -213.151% |
| AstraZeneca Pharma India Limited | 3.66 Billion INR | -4057.404% |
| Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -52603.472% |
| Brooks Laboratories Limited | 248.6 Million INR | -61125.458% |
| Megasoft Limited | 1.85 Billion INR | -8113.457% |
| ZIM Laboratories Limited | 2.08 Billion INR | -7214.969% |
| Strides Pharma Science Limited | 37.68 Billion INR | -303.941% |
| Neuland Laboratories Limited | 5.49 Billion INR | -2668.126% |
| Morepen Laboratories Limited | 4.45 Billion INR | -3312.877% |
| Hikal Limited | 12.99 Billion INR | -1071.283% |
| Indoco Remedies Limited | 10.34 Billion INR | -1371.695% |
| Aarti Pharmalabs Limited | 8.25 Billion INR | -1744.778% |
| Kilitch Drugs (India) Limited | 643.88 Million INR | -23538.938% |
| Mangalam Drugs & Organics Limited | 1.97 Billion INR | -7601.576% |
| Hester Biosciences Limited | 3.59 Billion INR | -4134.185% |